Filtered By:
Drug: Metformin
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 446 results found since Jan 2013.
Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke
Publication date: Available online 11 March 2021Source: Life SciencesAuthor(s): Sejal Sharma, Saeideh Nozohouri, Bhuvaneshwar Vaidya, Thomas Abbruscato
Source: Life Sciences - March 11, 2021 Category: Biology Source Type: research
Use of sodium –glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry
ConclusionIn a contemporary HF cohort with T2DM, SGLT2i use increased over time, was more common with specialist care, younger age, ischaemic heart disease, and preserved renal function, and was associated with lower mortality and morbidity.
Source: European Journal of Heart Failure - March 3, 2021 Category: Cardiology Authors: Peter M. Becher,
Benedikt Schrage,
Giulia Ferrannini,
Lina Benson,
Javed Butler,
Juan Jesus Carrero,
Francesco Cosentino,
Ulf Dahlstr öm,
Linda Mellbin,
Giuseppe M.C. Rosano,
Gianfranco Sinagra,
Davide Stolfo,
Lars H. Lund,
Gianluigi Savares Tags: Research Article Source Type: research
Omentin-1: protective impact on ischemic stroke via ameliorating atherosclerosis
This study is the first to summarize the comprehensive mechanisms between omentin-1 and atherosclerosis and to review the shielding effect of omentin-1 on IS. We shed light on omentin-1 as a novel therapeutic target for combating IS.PMID:33607071 | DOI:10.1016/j.cca.2021.02.004
Source: International Journal of Clinical Chemistry - February 19, 2021 Category: Chemistry Authors: Shiyi Lin Xin Li Jiabei Zhang Yuyang Zhang Source Type: research
Impact of Non-Alcoholic Fatty Liver Disease on Metabolic Comorbidities in Type 2 Diabetes Mellitus
Conclusion The coded prevalence of NAFLD in T2D patients is low, which is in contrast to published series. Enhancing disease awareness of NAFLD and screening recommendations in high risk populations will be beneficial for the active management of these patients. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents | Abstract | Full text
Source: Experimental and Clinical Endocrinology and Diabetes - February 18, 2021 Category: Endocrinology Authors: Labenz, Christian Kostev, Karel Alqahtani, Saleh A. Galle, Peter R. Schattenberg, J örn M. Tags: Article Source Type: research
Omentin-1: protective impact on ischemic stroke via ameliorating atherosclerosis.
This study is the first to summarize the comprehensive mechanisms between omentin-1 and atherosclerosis and to review the shielding effect of omentin-1 on IS. We shed light on omentin-1 as a novel therapeutic target for combating IS.
PMID: 33607071 [PubMed - as supplied by publisher]
Source: International Journal of Clinical Chemistry - February 16, 2021 Category: Chemistry Authors: Lin S, Li X, Zhang J, Zhang Y Tags: Clin Chim Acta Source Type: research
Feasibility trial of metformin XR in people with pre-diabetes and stroke (MIPPS)-randomised open blinded endpoint controlled trial
Publication date: April 2021Source: Journal of Clinical Neuroscience, Volume 86Author(s): Marjan Tabesh, Mariam Hachem, Lik-Hui Lau, Karen Borschmann, Leonid Churilov, Sarah A.L. Price, Priya Sumithran, Geoffrey Donnan, Jeffrey Zajac, Vincent Thijs, Elif I. Ekinci
Source: Journal of Clinical Neuroscience - February 3, 2021 Category: Neuroscience Source Type: research
Serum uric acid and diabetes: from pathophysiology to cardiovascular disease.
Abstract
Hyperuricemia, has been traditionally related to nephrolithiasis and gout. However, it has also been associated with the development of type 2 diabetes mellitus (T2DM) and cardiometabolic and cardiovascular diseases. Pathophysiologically, elevated serum uric acid (SUA) levels may be associated with abnormal lipid and glucose metabolism. In this narrative review, we consider the associations between hyperuricemia, hyperglycemia, atherosclerosis and thrombosis. Furthermore, we comment on the available evidence linking elevated SUA levels with the incidence and outcomes of coronary heart disease, stroke, per...
Source: Current Pharmaceutical Design - January 4, 2021 Category: Drugs & Pharmacology Authors: Katsiki N, Dimitriadis GD, Mikhailidis DP Tags: Curr Pharm Des Source Type: research
Hemichorea in ketotic hyperglycemia with hyperdense striatum mimicking hemorrhagic transformation in a patient using apixaban.
CONCLUSION: Diabetic striatopathy is a rare but treatable disorder and should be considered in patients with poorly controlled diabetes who present with hemichorea.
PMID: 33307650 [PubMed - as supplied by publisher]
Source: Neuroendocrinology Letters - December 16, 2020 Category: Endocrinology Tags: Neuro Endocrinol Lett Source Type: research
Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient
Metformin has been shown to have various cardiovascular benefits beyond its antihyperglycemic effects, including a reduction in stroke, heart failure, myocardial infarction, cardiovascular death, and all-cause...
Source: Cardiovascular Diabetology - November 24, 2020 Category: Cardiology Authors: Teerapat Nantsupawat, Wanwarang Wongcharoen, Siriporn C. Chattipakorn and Nipon Chattipakorn Tags: Review Source Type: research
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
CONCLUSIONS: Pioglitazone reduced or delayed the development of T2DM in people at increased risk of T2DM compared with placebo (low-certainty evidence) and compared with no intervention (moderate-certainty evidence). It is unclear whether the effect of pioglitazone is sustained once discontinued. Pioglitazone compared with metformin neither showed advantage nor disadvantage regarding the development of T2DM in people at increased risk (low-certainty evidence). The data and reporting of all-cause mortality, SAEs, micro- and macrovascular complications were generally sparse. None of the included studies reported on QoL or so...
Source: Cochrane Database of Systematic Reviews - November 19, 2020 Category: General Medicine Authors: Ipsen EØ, Madsen KS, Chi Y, Pedersen-Bjergaard U, Richter B, Metzendorf MI, Hemmingsen B Tags: Cochrane Database Syst Rev Source Type: research
Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis.
CONCLUSIONS: Both GLP-1 agonists and SGLT-2 inhibitors showed comparable cardiovascular outcomes in patients with type 2 diabetes. However, the SGLT-2 inhibitors were associated with more pronounced reduction of hospitalization for HF and lower risk of treatment discontinuation than GLP-1 agonists.
PMID: 33140391 [PubMed - as supplied by publisher]
Source: Cardiology Journal - November 3, 2020 Category: Cardiology Authors: Lee YM, Lee SH, Kim TH, Park EJ, Park YA, Jang JS Tags: Cardiol J Source Type: research
Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus.
Conclusion: SGLT2 inhibitors can be a good second-line drug to reduce the incidence of cardiovascular diseases compared with DPP-4 inhibitors or sulfonylureas in people with type 2 diabetes mellitus.
PMID: 33120439 [PubMed - as supplied by publisher]
Source: Diabetes and Metabolism Journal - October 31, 2020 Category: Endocrinology Tags: Diabetes Metab J Source Type: research
Risk of dementia in patients with periodontitis and related protective factors: a nationwide retrospective cohort study.
CONCLUSIONS: Periodontitis was a risk factor for dementia, while the use of statins and metformin may reduce the risk of dementia.
PMID: 32991015 [PubMed - as supplied by publisher]
Source: Journal of Clinical Periodontology - September 28, 2020 Category: Dentistry Authors: Lee CY, Chang CC, Lin CS, Yeh CC, Hu CJ, Wu CZ, Chen TL, Liao CC Tags: J Clin Periodontol Source Type: research
Repurposing Antidiabetic Drugs for Cardiovascular Disease
Metabolic diseases and diabetes represent an increasing global challenge for human health care. As associated with a strongly elevated risk of developing atherosclerosis, kidney failure and death from myocardial infarction or stroke, the treatment of diabetes requires a more effective approach than lowering blood glucose levels. This review summarizes the evidence for the cardioprotective benefits induced by antidiabetic agents, including sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP1-RA), along with sometimes conversely discussed effects of dipeptidyl peptidase-4 inhib...
Source: Frontiers in Physiology - September 14, 2020 Category: Physiology Source Type: research
